bk-2C-B Stats & Data

bk-2C-B was first characterized in the scientific literature in 2004 by pharmacologist Richard Glennon and his research team, who synthesized and studied the compound as part of investigations into phenethylamine structure-activity relationships. The substance remained largely obscure until 2013, when it emerged on European designer drug markets as a novel psychoactive substance. Following its market appearance, bk-2C-B maintained a consistent presence without generating significant enthusiasm or notoriety within the research chemical community. Despite this relatively muted reception, the compound was sampled by a substantial number of users over subsequent years. It was typically distributed in both pressed pill and powder forms. Its availability persisted in the gray market until regulatory measures were implemented across several countries beginning in 2016.

Forked from Subjective Effect Documentation work by Josie Kins, August 2016. Via dose.wiki (CC0).

The toxicity and long-term health effects of recreational βk-2C-B use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because Bk-2C-B is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried Bk-2C-B suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. It is strongly recommended that one use harm reduction practices when using this substance.

Effects aggregated from 9 experience reports (9 single-substance Erowid)

Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

Too few reports for bars: these effects come from 9 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

Also reported in combinations. In the 22 bk-2C-B reports where another drug was taken too, 4 (18.2%) mention hospital, emergency services or an overdose, 1 (4.5%) a seizure and 2 (9.1%) psychosis. In the 9 single-substance reports: 2, 1 and 0. These are not in the figures above: they cannot be put down to bk-2C-B alone, and a mention is not always something that happened to the writer.

Dose distribution from experience reports, one dose per report (the first listed). Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route: most are real heavy doses or overdoses, not mistakes.

From 53 of 60 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

Most co-occurring substances, as a share of all 31 reports filed under bk-2C-B; whiskers are 95% intervals

Most common forms and preparations, as a share of the 24 reports that give one; whiskers are 95% intervals

Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route.

Redosing behavior across 26 reports